Compare Crispr Therapeutics AG (CRSP) vs Equinor ASA (EQNR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Equinor ASA — how do they compare? Crispr Therapeutics AG trades at $53.93 (market cap $5.23B), while Equinor ASA trades at $40.81 (market cap $97.58B). The key difference: Equinor ASA is far larger — about 18.7× Crispr Therapeutics AG's market cap, and Equinor ASA pays a 3.81% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | EQNR | |
|---|---|---|
Market Cap | $5.23B | $97.58B |
Sector | Health | Energy |
52-Week High | $76.78 | $42.40 |
52-Week Low | $44.34 | $22.41 |
Enterprise Value | $3.65B | $106.28B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
EQNR trades at $40.99, up 5.32% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 40% year-over-year despite an earnings miss, driven by higher energy prices and production. Recent news highlights a 22.2% monthly rally and ongoing share buybacks. Valuation ratios appear attractive with a P/E of 11.09 and EV/EBITDA of 2.3, while profitability metrics like a 21.32% ROE indicate efficient capital use.
The outlook for EQNR is positive, with opportunities from strategic investments in subsea projects and sustained cash flow generation supporting dividends and buybacks. Risks include volatility in oil and gas prices, execution challenges in growth projects, and potential regulatory shifts impacting energy markets. Analyst sentiment is mixed but leans cautious, with 56.53% holding a neutral stance amid valuation concerns after recent gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →
